NasdaqGS:INVAPharmaceuticals
Innoviva (INVA) One Off Gain Driven 65.9% Margin Challenges Bullish Earnings Narratives
Innoviva (INVA) has wrapped up FY 2025 with Q4 revenue of US$114.6 million and basic EPS of US$2.19, capping a trailing 12 month period where revenue was US$411.3 million and basic EPS reached US$4.02 alongside a reported net profit margin of 65.9% that was lifted by a US$161.6 million one off gain. Over the past few quarters, the company has seen revenue move from US$88.6 million in Q1 2025 to US$114.6 million in Q4 2025, while basic EPS shifted from a loss of US$0.74 in Q1 2025 to US$2.19...